Lead Product(s) : INNA-051
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : University of Maryland
Deal Size : Undisclosed
Deal Type : Partnership
ENA and Maryland Launch Phase 2 Study for INNA-051 Antiviral Therapy
Details : The partnership aims to advance the company’s lead product, INNA-051, is being developed as a convenient, once-a-week nasal dry powder product to reduce the impact of viral respiratory infections.
Product Name : INNA-051
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
April 09, 2025
Lead Product(s) : INNA-051
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : University of Maryland
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : INNA-051
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
ENA Respiratory Completes Phase Ib Dosing of INNA-051 in Older Adults for Antiviral Study
Details : INNA-051 is a TLR2/6 agonist, small molecule drug candidate in development as an innate immune modulator, delivered using a nasal spray. It is being evaluated for viral respiratory infections.
Product Name : INNA-051
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 22, 2025
Lead Product(s) : INNA-051
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CampETEC
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
NMRC Reports Results for Campylobacter Controlled Human Infection Model Study
Details : Immuron vaccine drug candidate CampETEC, is being evaluating for the diarrhoea caused by Campylobacter and including Enterotoxigenic Escherichia coli infections.
Product Name : CampETEC
Product Type : Vaccine
Upfront Cash : Inapplicable
April 10, 2024
Lead Product(s) : CampETEC
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : R327
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : RECCE 327 (R327) is a rapid and irreversible bactericidal against gram-negative escherichia coli (E. coli) bacteria, in both active and stationary phase cells, which is being investigated as a treatment for sepsis and complicated/uncomplicated urinary tr...
Product Name : RECCE 327
Product Type : Antibiotic
Upfront Cash : Inapplicable
July 20, 2023
Lead Product(s) : R327
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Gamma-PN3
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : GPN Vaccines
Deal Size : Undisclosed
Deal Type : Partnership
BioCina Expands Partnership with GPN Vaccines
Details : Under the agreement, BioCina will manufacture large-scale cGMP batches for proprietary engineered whole-cell vaccine called Gamma-PN3 against Streptococcus pneumoniae.
Product Name : Gamma-PN3
Product Type : Vaccine
Upfront Cash : Undisclosed
June 11, 2023
Lead Product(s) : Gamma-PN3
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : GPN Vaccines
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : CampETEC
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : US Naval Medical Research Command
Deal Size : Inapplicable
Deal Type : Inapplicable
Immuron Announces First Patients Enrolled in Campylobacter Challenge Clinical Study
Details : Immuron vaccine drug candidate CampETEC, which is being evaluating for the diarrhoea caused by Campylobacter and including Enterotoxigenic Escherichia coli infections.
Product Name : CampETEC
Product Type : Vaccine
Upfront Cash : Inapplicable
April 12, 2023
Lead Product(s) : CampETEC
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : US Naval Medical Research Command
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : R327
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Company report that in cohort seven of a Phase 1 clinical trial, RECCE® 327 (R327) intravenously dosed at 6,000mg (a 120-fold increase from cohort one at 50mg) over a 1-hour infusion demonstrated no serious adverse effects among 10 healthy male subjects...
Product Name : RECCE 327
Product Type : Antibiotic
Upfront Cash : Inapplicable
August 23, 2022
Lead Product(s) : R327
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : R327
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Recce Pharmaceuticals Announces Safety Committee Clears Next Dose in Phase I Study of RECCE® 327
Details : RECCE 327, a first new class of antibiotics with a universal mechanism of action that allows its compounds to continuously kill bacteria and multi-drug resistant superbugs, demonstrating good safety and tolerability profile – unanimously recommending c...
Product Name : RECCE 327
Product Type : Antibiotic
Upfront Cash : Inapplicable
August 03, 2022
Lead Product(s) : R327
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : R327
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : RECCE® 327 (R327) demonstrated a good safety and tolerability profile among 10 healthy male subjects intravenously dosed at 4,000mg (an 80-fold increase from cohort one at 50mg).
Product Name : RECCE 327
Product Type : Antibiotic
Upfront Cash : Inapplicable
June 22, 2022
Lead Product(s) : R327
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : R327
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : In cohort five of a Phase I clinical trial, RECCE 327 (R327) demonstrated a good safety and tolerability profile among 10 healthy male subjects intravenously dosed at 2,000mg.
Product Name : RECCE 327
Product Type : Antibiotic
Upfront Cash : Inapplicable
May 23, 2022
Lead Product(s) : R327
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable